{"pmid":32410319,"title":"Coronavirus Disease 2019 and Viral Hepatitis coinfection: Provide guidelines for integrated screening and treatment.","text":["Coronavirus Disease 2019 and Viral Hepatitis coinfection: Provide guidelines for integrated screening and treatment.","The rapid spread of severe acute respiratory syndrome coronavirus 2, the virus, that causes Coronavirus disease 2019 (COVID-19) threatens global health. Emerging evidence and past experience from other coronaviruses suggests that people with underlying liver disease including viral hepatitis could be at risk of disease severity and mortality. However, with the present relatively low screening rates for the most prevalent viral hepatitis - Hepatitis B and C, many COVID-19 cases especially in low middle income countries are unlikely to be screened for viral hepatitis coinfection. Without active screening, little will be known about the clinical and epidemiological manifestations which could negatively impact public health efforts. In this commentary, we call for systematic and integrated screening of Hepatitis B and C for COVID-19 confirmed patients. We also call for guidelines for management and treatment as well as research to understand the epidemiology of coinfection This article is protected by copyright. All rights reserved.","J Med Virol","Odjidja, Emmanuel Nene","Longo, Valentina Laurita","Rizzatti, Gianenrico","Bandoh, Salome","32410319"],"abstract":["The rapid spread of severe acute respiratory syndrome coronavirus 2, the virus, that causes Coronavirus disease 2019 (COVID-19) threatens global health. Emerging evidence and past experience from other coronaviruses suggests that people with underlying liver disease including viral hepatitis could be at risk of disease severity and mortality. However, with the present relatively low screening rates for the most prevalent viral hepatitis - Hepatitis B and C, many COVID-19 cases especially in low middle income countries are unlikely to be screened for viral hepatitis coinfection. Without active screening, little will be known about the clinical and epidemiological manifestations which could negatively impact public health efforts. In this commentary, we call for systematic and integrated screening of Hepatitis B and C for COVID-19 confirmed patients. We also call for guidelines for management and treatment as well as research to understand the epidemiology of coinfection This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Odjidja, Emmanuel Nene","Longo, Valentina Laurita","Rizzatti, Gianenrico","Bandoh, Salome"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32410319","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1002/jmv.26021","keywords":["covid-19","integrated treatment","systematic screening","viral hepatitis"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666897319062142976,"score":9.490897,"similar":[{"pmid":32319207,"title":"COVID-19 and viral hepatitis elimination programs: Are we stepping backward?","text":["COVID-19 and viral hepatitis elimination programs: Are we stepping backward?","As Mendlowitz and colleagues mentioned in a recent commentary, the World Health Organization set a goal for the elimination of viral hepatitis until 2030. This means that the number of newly infected persons and related mortality should be decreased by 90% and 65%, respectively. The elimination programs focus on different parts such as testing, treatment, immunization against hepatitis B virus (HBV), preventing mother to child transmission, blood safety, and harm reduction. Now, COVID-19 is spreading fast throughout the world and more than one million people have been affected by this virus so far. While all attentions are now on providing effective medicines and vaccines for COVID-19, we should not forget other viruses and diseases.","Liver Int","Karimi-Sari, Hamidreza","Rezaee-Zavareh, Mohammad Saeid","32319207"],"abstract":["As Mendlowitz and colleagues mentioned in a recent commentary, the World Health Organization set a goal for the elimination of viral hepatitis until 2030. This means that the number of newly infected persons and related mortality should be decreased by 90% and 65%, respectively. The elimination programs focus on different parts such as testing, treatment, immunization against hepatitis B virus (HBV), preventing mother to child transmission, blood safety, and harm reduction. Now, COVID-19 is spreading fast throughout the world and more than one million people have been affected by this virus so far. While all attentions are now on providing effective medicines and vaccines for COVID-19, we should not forget other viruses and diseases."],"journal":"Liver Int","authors":["Karimi-Sari, Hamidreza","Rezaee-Zavareh, Mohammad Saeid"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32319207","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/liv.14486","keywords":["covid-19","hepatitis b","hepatitis c","viral hepatitis","elimination"],"topics":["General Info"],"weight":1,"_version_":1666138493721509888,"score":266.85287},{"pmid":32369204,"title":"Hepatic involvement in COVID-19 patients: pathology, pathogenesis and clinical implications [Review].","text":["Hepatic involvement in COVID-19 patients: pathology, pathogenesis and clinical implications [Review].","During the clinical course of COVID-19, it has been observed that hepatic injury occurs in a significant proportion of patients, particularly in those with severe or critical illness. Mild increase in sinusoidal lymphocytic infiltration and multifocal hepatic necrosis are the main pathologic changes. Direct viral induced cellular injuries and potential hepatotoxicity from therapeutic drugs are two likely underlying mechanisms. In addition, preexisting chronic liver disease exacerbated during COVID-19, and COVID-19-related hyper-inflammatory reactions may contribute to liver injury as well. Further studies of additional autopsy cases will help clarifying these possibilities. This article is protected by copyright. All rights reserved.","J Med Virol","Li, Yueying","Xiao, Shu-Yuan","32369204"],"abstract":["During the clinical course of COVID-19, it has been observed that hepatic injury occurs in a significant proportion of patients, particularly in those with severe or critical illness. Mild increase in sinusoidal lymphocytic infiltration and multifocal hepatic necrosis are the main pathologic changes. Direct viral induced cellular injuries and potential hepatotoxicity from therapeutic drugs are two likely underlying mechanisms. In addition, preexisting chronic liver disease exacerbated during COVID-19, and COVID-19-related hyper-inflammatory reactions may contribute to liver injury as well. Further studies of additional autopsy cases will help clarifying these possibilities. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Li, Yueying","Xiao, Shu-Yuan"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369204","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25973","keywords":["covid-19","coronavirus","hepatotoxicity","jmv25973","liver injury","pathogenesis"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138496240189441,"score":238.73474},{"pmid":32253172,"pmcid":"PMC7174834","title":"Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now?","text":["Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now?","Since December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19), has posed a serious threat to global health and is currently causing a major pandemic. While patients typically present with fever and a respiratory illness, mounting evidence indicates that patients might also report extra-pulmonary manifestations, including those affecting the liver and gastrointestinal tract. This involvement may have important implications to the disease management, transmission, and prognosis, especially in patients with pre-existing hepatic or digestive co-morbidities. In this review, the characteristics and possible explanations of hepatic and gastrointestinal involvement caused by SARS-CoV-2 infection are summarized, adding to our knowledge of the spectrum of COVID-19. In addition, preventive measures implemented in endoscopy departments to prevent further dissemination of SARS-CoV-2 infection are proposed.","Arab J Gastroenterol","Musa, Sherief","32253172"],"abstract":["Since December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19), has posed a serious threat to global health and is currently causing a major pandemic. While patients typically present with fever and a respiratory illness, mounting evidence indicates that patients might also report extra-pulmonary manifestations, including those affecting the liver and gastrointestinal tract. This involvement may have important implications to the disease management, transmission, and prognosis, especially in patients with pre-existing hepatic or digestive co-morbidities. In this review, the characteristics and possible explanations of hepatic and gastrointestinal involvement caused by SARS-CoV-2 infection are summarized, adding to our knowledge of the spectrum of COVID-19. In addition, preventive measures implemented in endoscopy departments to prevent further dissemination of SARS-CoV-2 infection are proposed."],"journal":"Arab J Gastroenterol","authors":["Musa, Sherief"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253172","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ajg.2020.03.002","keywords":["covid-19","endoscopy","gastrointestinal tract","liver","sars-cov-2"],"topics":["Prevention","Diagnosis","Mechanism"],"weight":1,"_version_":1666138493080829953,"score":222.42014},{"pmid":32403255,"title":"COVID-19, MERS and SARS with Concomitant Liver Injury-Systematic Review of the Existing Literature.","text":["COVID-19, MERS and SARS with Concomitant Liver Injury-Systematic Review of the Existing Literature.","The novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection has been predominantly linked to respiratory distress syndrome, but gastrointestinal symptoms and hepatic injury have also been reported. The mechanism of liver injury is poorly understood and may result as a consequence of viral hepatitis, systemic inflammatory response, gut barrier and microbiome alterations, intensive care treatment or drug toxicity. The incidence of hepatopathy among patients with coronavirus disease 2019 (COVID-19) is unclear, but studies have reported liver injury in patients with SARS and Middle East respiratory syndrome (MERS). We aimed to systematically review data on the prevalence of hepatic impairments and their clinical course in SARS and MERS Coronaviridae infections. A systematic literature search (PubMed/Embase/Cinahl/Web of Science) according to preferred reporting items for systematic review and meta-analysis protocols (PRISMA) was conducted from database inception until 17/03/2020 for studies that evaluated the incidence of hepatic abnormalities in SARS CoV-1, SARS CoV-2 and MERS infected patients with reported liver-related parameters. A total of forty-three studies were included. Liver anomalies were predominantly mild to moderately elevated transaminases, hypoalbuminemia and prolongation of prothrombin time. Histopathology varied between non-specific inflammation, mild steatosis, congestion and massive necrosis. More studies to elucidate the mechanism and importance of liver injury on the clinical course and prognosis in patients with novel SARS-CoV-2 infection are warranted.","J Clin Med","Kukla, Michal","Skonieczna-Zydecka, Karolina","Kotfis, Katarzyna","Maciejewska, Dominika","Loniewski, Igor","Lara, Luis F","Pazgan-Simon, Monika","Stachowska, Ewa","Kaczmarczyk, Mariusz","Koulaouzidis, Anastasios","Marlicz, Wojciech","32403255"],"abstract":["The novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection has been predominantly linked to respiratory distress syndrome, but gastrointestinal symptoms and hepatic injury have also been reported. The mechanism of liver injury is poorly understood and may result as a consequence of viral hepatitis, systemic inflammatory response, gut barrier and microbiome alterations, intensive care treatment or drug toxicity. The incidence of hepatopathy among patients with coronavirus disease 2019 (COVID-19) is unclear, but studies have reported liver injury in patients with SARS and Middle East respiratory syndrome (MERS). We aimed to systematically review data on the prevalence of hepatic impairments and their clinical course in SARS and MERS Coronaviridae infections. A systematic literature search (PubMed/Embase/Cinahl/Web of Science) according to preferred reporting items for systematic review and meta-analysis protocols (PRISMA) was conducted from database inception until 17/03/2020 for studies that evaluated the incidence of hepatic abnormalities in SARS CoV-1, SARS CoV-2 and MERS infected patients with reported liver-related parameters. A total of forty-three studies were included. Liver anomalies were predominantly mild to moderately elevated transaminases, hypoalbuminemia and prolongation of prothrombin time. Histopathology varied between non-specific inflammation, mild steatosis, congestion and massive necrosis. More studies to elucidate the mechanism and importance of liver injury on the clinical course and prognosis in patients with novel SARS-CoV-2 infection are warranted."],"journal":"J Clin Med","authors":["Kukla, Michal","Skonieczna-Zydecka, Karolina","Kotfis, Katarzyna","Maciejewska, Dominika","Loniewski, Igor","Lara, Luis F","Pazgan-Simon, Monika","Stachowska, Ewa","Kaczmarczyk, Mariusz","Koulaouzidis, Anastasios","Marlicz, Wojciech"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32403255","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/jcm9051420","keywords":["covid-19","mers","sars","sars-cov-2","coronavirus","liver","pandemic"],"topics":["Treatment","Diagnosis","Mechanism"],"weight":1,"_version_":1666802845321527296,"score":209.88393},{"pmid":32476796,"pmcid":"PMC7243653","title":"Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review.","text":["Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review.","The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) that causes coronavirus disease-2019 (COVID-19) is a global pandemic, manifested by an infectious pneumonia. Although patients primarily present with fever, cough and dyspnea, some patients also develop gastrointestinal (GI) and hepatic manifestations. The most common GI symptoms reported are diarrhea, nausea, vomiting, and abdominal discomfort. Liver chemistry abnormalities are common and include elevation of aspartate transferase, alanine transferase, and total bilirubin. Studies have shown that SARS-CoV-2 infects the GI tract via its viral receptor angiotensin converting enzyme II, which is expressed on enterocytes of the ileum and colon. Viral RNA has also been isolated from stool specimens of COVID-19 patients, which raised the concern for fecal-oral transmission in addition to droplet transmission. Although indirect evidence has suggested possible fecal-oral transmission of SARS-CoV-2, more effort is needed to establish the role of the fecal-oral transmission route. Further research will help elucidate the association between patients with underlying GI diseases, such as chronic liver disease and inflammatory bowel disease, and severity of COVID-19. In this review, we summarize the data on GI involvement to date, as well as the impact of COVID-19 on underlying GI diseases.","World J Gastroenterol","Cha, Ming Han","Regueiro, Miguel","Sandhu, Dalbir S","32476796"],"abstract":["The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) that causes coronavirus disease-2019 (COVID-19) is a global pandemic, manifested by an infectious pneumonia. Although patients primarily present with fever, cough and dyspnea, some patients also develop gastrointestinal (GI) and hepatic manifestations. The most common GI symptoms reported are diarrhea, nausea, vomiting, and abdominal discomfort. Liver chemistry abnormalities are common and include elevation of aspartate transferase, alanine transferase, and total bilirubin. Studies have shown that SARS-CoV-2 infects the GI tract via its viral receptor angiotensin converting enzyme II, which is expressed on enterocytes of the ileum and colon. Viral RNA has also been isolated from stool specimens of COVID-19 patients, which raised the concern for fecal-oral transmission in addition to droplet transmission. Although indirect evidence has suggested possible fecal-oral transmission of SARS-CoV-2, more effort is needed to establish the role of the fecal-oral transmission route. Further research will help elucidate the association between patients with underlying GI diseases, such as chronic liver disease and inflammatory bowel disease, and severity of COVID-19. In this review, we summarize the data on GI involvement to date, as well as the impact of COVID-19 on underlying GI diseases."],"journal":"World J Gastroenterol","authors":["Cha, Ming Han","Regueiro, Miguel","Sandhu, Dalbir S"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476796","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3748/wjg.v26.i19.2323","keywords":["covid-19","diarrhea","gastrointestinal","inflammatory bowel disease","liver","sars-cov-2"],"e_drugs":["Alanine","Aspartic Acid","Bilirubin"],"topics":["Diagnosis","Mechanism","Transmission"],"weight":1,"_version_":1668532089544245248,"score":204.8026}]}